Form 4: Incyte EVP & Chief Medical Officer Reports Future Tax-Related Stock Disposition Under 10b5-1 Plan

Steven H. Stein, Incyte's EVP & Chief Medical Officer, reported a future disposition of 12,714 common shares on July 2, 2025, to cover tax withholding obligations related to equity awards under a Rule 10b5-1 plan.

Summary

• Steven H. Stein, Executive Vice President and Chief Medical Officer of Incyte Corp. (INCY), reported a disposition of common stock.
• The transaction, dated July 2, 2025, involved the disposition of 12,714 shares of common stock at a price of $68.17 per share.
• This disposition was made to satisfy tax withholding obligations due at the settlement of previously reported restricted stock units (RSUs) or earned performance shares.
• The transaction was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Steven H. Stein beneficially owns 112,418 shares of Incyte common stock.
• The total beneficial ownership includes an aggregate of 94,907 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not yet vested.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event related to equity compensation, which is a neutral event for the company's operational performance or strategic direction. It does not reflect a discretionary sale by the insider.

Negatives

• A reduction of 12,714 shares in direct beneficial ownership due to tax withholding, although this is a routine and non-discretionary event.

Future Outlook

The document details a future, pre-planned transaction for tax withholding purposes, but does not provide broader forward-looking statements or guidance regarding the company's performance or strategic outlook.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation. Such tax-related dispositions are common across industries when equity awards vest, and this specific filing does not indicate any broader industry trends or competitive shifts.

Comparison to Industry Standards

• The disposition of shares to cover tax withholding obligations upon the vesting of equity awards is a standard and widely accepted practice for executive compensation across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice, providing a pre-arranged schedule for insider stock sales to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: A minor, non-discretionary reduction in direct insider ownership, which is a common occurrence and generally has no material impact on shareholder value or company operations.

Key Dates

Keywords

Incyte, INCY, Form 4, insider transaction, stock disposition, tax withholding, executive compensation, Steven H. Stein, Rule 10b5-1